Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients DOI Creative Commons
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 5, 2023

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics. Methods Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factor that influenced prognosis. Drug sensitive prediction performed evaluate value constructed model. Results VCAN, CD3G C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68+ macrophages CD8+ associated better In addition, significantly macrophages, CD4+ ratio, indicating it could play an role anti-tumor immunity riskScore model based on RNASeq data work well predicting drug sensitivity. Conclusion DLBCL, also exert certain impact sensitivity

Language: Английский

RAI2 acts as a tumor suppressor with functional significance in gastric cancer DOI Creative Commons
Xiaoli Lou, Wei Deng,

Lixiong Shuai

et al.

Aging, Journal Year: 2023, Volume and Issue: 15(21), P. 11831 - 11844

Published: Oct. 25, 2023

Metastasis of gastric cancer (GC) is one the major causes death among GC patients. metastasis involves numerous biological processes, yet specific molecular mechanisms have not been elucidated. Here, we report a novel tumor suppressor, retinoic acid-induced 2 (RAI2), which located in Xp22 region chromosome and plays role inhibiting growth invasion. In this study, integrated analysis The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) datasets immunohistochemistry staining data suggested that RAI2 expression samples was low. Moreover, immune infiltration indicated low associated with higher intensity tumor-infiltrating lymphocytes (TILs) an abundance Programmed ligand 1 (PD-L1) expression. set enrichment (GSEA) further revealed regulated some pathways including GAP junction, focal adhesion ECM receptor interaction pathway, regulation, PI3K-Akt signaling, MAPK cell cycle, DNA replication. Furthermore, knockdown promoted proliferation, migration, invasion vitro. Taken together, these results suggest suppressor could be potential target for development anti-cancer strategies GC.

Language: Английский

Citations

2
Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients DOI Creative Commons
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

eLife, Journal Year: 2024, Volume and Issue: 13

Published: Jan. 31, 2024

Background: Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics. Methods: Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factors that influenced prognosis. Drug-sensitive prediction performed evaluate value model. Results: VCAN, CD3G, C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68 + macrophages CD8 associated better In addition, CD3G+T significantly macrophages, CD4 cells, +T ratio, indicating it could play an role anti-tumor immunity riskScore model constructed based on RNASeq data C1QB, CD3G work well predicting drug sensitivity. Conclusions: DLBCL, also exert certain impact sensitivity Funding: This supported by Shenzhen High-level Hospital Construction Fund CAMS Innovation Medical Sciences (CIFMS) (2022-I2M-C&T-B-062).

Language: Английский

Citations

0
Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients DOI Open Access
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

Published: Jan. 31, 2024

Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics.Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factor that influenced prognosis. Drug sensitive prediction performed evaluate value constructed model.VCAN, CD3G C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68+ macrophages CD8+ associated better In addition, significantly macrophages, CD4+ ratio, indicating it could play an role anti-tumor immunity riskScore model based on RNASeq data VCAN, work well predicting drug sensitivity.VCAN, DLBCL, also exert certain impact sensitivity

Language: Английский

Citations

0
eLife assessment: Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients DOI Open Access
Mohammad Mahdi Karimi

Published: Jan. 31, 2024

Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics.Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factor that influenced prognosis. Drug sensitive prediction performed evaluate value constructed model.VCAN, CD3G C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68+ macrophages CD8+ associated better In addition, significantly macrophages, CD4+ ratio, indicating it could play an role anti-tumor immunity riskScore model based on RNASeq data VCAN, work well predicting drug sensitivity.VCAN, DLBCL, also exert certain impact sensitivity

Language: Английский

Citations

0
Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis DOI
Roberto J. Alcazar‐Félix, Abhinav Srinath, Stephanie Hage

et al.

Journal of Stroke and Cerebrovascular Diseases, Journal Year: 2024, Volume and Issue: 33(7), P. 107699 - 107699

Published: March 27, 2024

Language: Английский

Citations

0
Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients DOI Open Access
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

Published: June 19, 2024

Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics.Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factor that influenced prognosis. Drug sensitive prediction performed evaluate value constructed model.VCAN, CD3G C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68+ macrophages CD8+ associated better In addition, significantly macrophages, CD4+ ratio, indicating it could play an role anti-tumor immunity riskScore model based on RNASeq data VCAN, work well predicting drug sensitivity.VCAN, DLBCL, also exert certain impact sensitivity

Language: Английский

Citations

0
Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients DOI Creative Commons
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

eLife, Journal Year: 2024, Volume and Issue: 13

Published: July 9, 2024

Background: Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics. Methods: Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factors that influenced prognosis. Drug-sensitive prediction performed evaluate value model. Results: VCAN, CD3G, C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68 + macrophages CD8 associated better In addition, CD3G+T significantly macrophages, CD4 cells, +T ratio, indicating it could play an role anti-tumor immunity riskScore model constructed based on RNASeq data C1QB, CD3G work well predicting drug sensitivity. Conclusions: DLBCL, also exert certain impact sensitivity Funding: This supported by Shenzhen High-level Hospital Construction Fund CAMS Innovation Medical Sciences (CIFMS) (2022-I2M-C&T-B-062).

Language: Английский

Citations

0
Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment DOI Creative Commons
Jiao Zhou,

Shan Shi,

Y. Qiu

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: April 3, 2023

Introduction: Research has revealed that the tumor microenvironment (TME) is associated with progression of malignancy. The combination meaningful prognostic biomarkers related to TME expected be a reliable direction for improving diagnosis and treatment non-small cell lung cancer (NSCLC). Method Result: Therefore, better understand connection between survival outcomes NSCLC, we used “DESeq2” R package mine differentially expressed genes (DEGs) two groups NSCLC samples according optimal cutoff value immune score through ESTIMATE algorithm. A total 978 up-DEGs 828 down-DEGs were eventually identified. fifteen-gene signature was established via LASSO Cox regression analysis further divided patients into risk sets. outcome high-risk significantly worse than low-risk in both TCGA external validation sets ( p-value < 0.05). gene showed high predictive accuracy (1-year area under time-dependent ROC curve (AUC) = 0.722, 2-year AUC 0.708, 3-year 0.686). nomogram comprised clinicopathological information constructed, calibration plots curves applied, KEGG GSEA analyses epithelial-mesenchymal transition (EMT) pathway, E2F target pathway immune-associated mainly involved group. Further somatic mutation conducted compare differences groups. Drug sensitivity provides potential basis clinical treatment. Finally, EREG ADH1C selected as key overlapping results from PPI multiple analyses. They verified by comparing mRNA expression lines protein HPA database, confirmed effectiveness genes. Conclusion: In conclusion, obtained an immune-related mechanism sensitive drugs underling prognosis model, which may provide accurate prediction available strategies NSCLC.

Language: Английский

Citations

0
Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients DOI Creative Commons
Zhenbang Ye, Ning Huang,

Yongliang Fu

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 5, 2023

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant lymphoma. Although various treatments have been developed, limited efficacy calls for more and further exploration its characteristics. Methods Datasets from Gene Expression Omnibus (GEO) database were used identifying tumor purity DLBCL. Survival analysis was employed analyzing prognosis DLBCL patients. Immunohistochemistry conducted to detect important factor that influenced prognosis. Drug sensitive prediction performed evaluate value constructed model. Results VCAN, CD3G C1QB identified as three key genes impacted outcome patients both in GEO datasets samples our center. Among them, VCAN CD3G+ T cells correlated with favorable prognosis, worse The ratio CD68+ macrophages CD8+ associated better In addition, significantly macrophages, CD4+ ratio, indicating it could play an role anti-tumor immunity riskScore model based on RNASeq data work well predicting drug sensitivity. Conclusion DLBCL, also exert certain impact sensitivity

Language: Английский

Citations

0